ARQT
Arcutis Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$23.90
+1.01%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
30.3x
EV/EBITDA
65.3x
Market Cap
$3.00B
MomentumView details →
1D Return
+1.01%
YTD Return
−18.13%
RSI (14)
36.8
ValuationView details →
P/E (Fwd)
30.3x
EV/EBITDA
65.3x
Market Cap
$3.00B
RSI (14)
36.8
MomentumView details →
1D Return
+1.01%
YTD Return
−18.13%
SummaryUpdated Jun 1, 2026
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a commercial-stage biopharmaceutical company founded in 2016 and headquartered in Westlake Village, California. The company went public in January 2020 and focuses on developing and commercializing innovative treatments for dermatological diseases. Arcutis has successfully transitioned from a clinical-stage company to a commercial enterprise, with its flagship product ZORYVE generating significant revenue growth since its initial launch for plaque psoriasis in 2022.
Similar companies
Latest newsMore news →
Oruka Therapeutics, Inc. appointed Todd Edwards as Chief Commercial Officer, effective with a base salary of $525,000, a target bonus of 40% of annual base salary, a signing bonus of $200,000, and equity grants including a stock option for 20,000 shares and restricted stock units for 100,000 shares of Oruka common stock.12d agoArcutis Biotherapeutics reported second quarter 2026 financial results with ZORYVE net product revenue of $129.9 million, up 59% year-over-year, and raised its full-year 2026 net product sales guidance to $525 million-$540 million.30d ago